🇺🇸 FDA
Patent

US 10172841

Inhibition of crystal growth of roflumilast

granted A61KA61K31/44A61K45/06

Quick answer

US patent 10172841 (Inhibition of crystal growth of roflumilast) held by Arcutis, Inc. expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcutis, Inc.
Grant date
Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014